Pediatric low-grade gliomas (PLGGs) are a heterogeneous group of tumors that require multiple therapeutic interventions and have variable outcomes. As a result of this and the chronic nature of the disease, management of such tumors has long been considered the art of oncology, with different oncologists taking different approaches with no real consensus on the best way to manage these patients. The last decade has transformed the way clinicians approach PLGGs, both with respect to the understanding of the initial molecular alterations that drive tumorigenesis^1-3 and the long-term consequences of the disease.^4,5 Although, as noted by Jones et al,⁶ some controversies remain, we have now reached the point at which some treatment approach recommendations can be made. For the treating physician, it is important to decipher the former from the latter.

中文翻译：

---

回复DTW Jones等

小儿低度神经胶质瘤（PLGG）是一组异质性肿瘤，需要多种治疗干预并具有不同的预后。由于这种疾病以及该疾病的慢性性质，长期以来一直将这种肿瘤的治疗视为肿瘤学领域，不同的肿瘤学家采取了不同的方法，而在治疗这些患者的最佳方法上并没有真正的共识。过去十年改变了临床医生处理PLGG的方式，无论是对驱动^1-3肿瘤发生的初始分子变化以及该疾病的长期后果的理解。^4,5尽管如Jones等人所述，⁶仍有一些争议，我们现在可以提出一些治疗方法的建议。对于主治医师，将前者与后者区分开是很重要的。